Cystatin C as a biomarker of chronic kidney disease: latest developments.

ABSTRACT:

Introduction

Chronic kidney disease (CKD) is common, occurring in over 10% of individuals globally, and is increasing in prevalence. The limitations of traditional biomarkers of renal dysfunction, such as serum creatinine, have been well demonstrated in the literature. Therefore, augmenting clinical assessment with newer biomarkers, such as serum cystatin C, has the potential to improve disease monitoring and patient care.

Areas covered

The present paper assesses the utility and limitations of serum cystatin C as a biomarker for CKD in light of the current literature.

Expert opinion

Serum cystatin C has been well established as an early and accurate biomarker of CKD that is particularly helpful in patients for whom creatinine is an inadequate marker or for whom more c

SUBMITTER: Benoit SW 

PROVIDER: S-EPMC7657956 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature